2. Apoptosis Metabolic Enzyme/Protease NF-κB Immunology/Inflammation
  3. Caspase Apoptosis RIP kinase Glutathione Peroxidase Reactive Oxygen Species (ROS)
  4. Z-VAD-FMK

Z-VAD-FMK  (Synonyms: Z-VAD(OH)-FMK; Caspase Inhibitor VI)

製品番号: HY-16658B 純度: 98.0%
COA 取扱説明書 Technical Support

Z-VAD-FMK is a pan-caspase inhibitor and also an ICE-like protease inhibitor, which inhibits apoptosis by preventing the processing of CPP32 to its active form. Z-VAD-FMK sensitivity varies primarily due to differential expression of receptor-interacting protein 1 (RIP1). Z-VAD-FMK limits the cryopreservation-induced apoptosis by reducing caspase-3 activity of in vitro produced bovine embryos. Z-VAD-FMK is immunosuppressive in vitro and inhibits T cell proliferation without blocking the processing of caspase-8 and caspase-3. Z-VAD-FMK leads to a decrease in intracellular glutathione (GSH) with a concomitant increase in reactive oxygen species (ROS) levels in activated T cells. Z-VAD-FMK is due to oxidative stress via the depletion of GSH. Z-VAD-FMK can be used for the study of acute pancreatitis.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 161401-82-7

容量 価格（税別） 在庫状況 数量
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 341 在庫あり
Solution
10 mM * 1 mL in DMSO USD 341 在庫あり
Solid
1 mg $147 在庫あり
5 mg $310 在庫あり
10 mg $527 在庫あり
25 mg $880 在庫あり
50 mg $1320 在庫あり
100 mg $1980 在庫あり
200 mg   お問い合わせ  
500 mg   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 740 publication(s) in Google Scholar

Other Forms of Z-VAD-FMK:

Z-VAD-FMK 関連抗体

Top Publications Citing Use of Products

顧客検証

WB
IF
Cell Proliferation/Viability Assay

    Z-VAD-FMK purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Aug 7;16(1):7309.  [Abstract]

    hBMECs were pretreated with Necrosulfonamide (NSA) (20 μM) or zVAD alone or in combination for 0.5 h, followed by infection with RS218 at an MOI of 1 or 10. LDH release (n=6 biologically independent samples) was assayed.

    Z-VAD-FMK purchased from MedChemExpress. Usage Cited in: Bone Res. 2024 Aug 27;12(1):47.  [Abstract]

    Cell death induced by HOXC10 inhibition plus TTI-101 cotreatment was rescued by ferroptosis inhibitors. Cells with or without knockdown of HOXC10 were pretreated with HOXC10 TTI-101 for 12 h and then treated the indicated cell death inhibitors (3-MA-1 mmol/L, Necrostatin-1-20 μmol/L, Ferrostatin-1-2 μmol/L, Z-VAD-FMK-10 μmol/L, Glutathione-1 mmol/L, Deferoxamine (DFO-100 μmol/L)) for an additional 72 h. Effect on ferroptosis inhibitors rescuing cell death was assessed by cell viability assays.

    Z-VAD-FMK purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2023 Jun;25(6):836-847.  [Abstract]

    Cell viability of HeLa cells treated with brequinar (0.3 μM) or/and AICAR (40 μM)/A-769662 (200 μM)/MK-8722 (1 μM) for 72 h following pretreatment with vehicle or cell death inhibitors for 24 h. Ferr-1 (10 μM), Z-VAD-FMK (10 μM), necrosulfonamide (2 μM).

    Z-VAD-FMK purchased from MedChemExpress. Usage Cited in: Adv Funct Mater. 2023 May 14.

    The viability of MC38 cells treated with PAD@MS for 48 h in the presence or absence of 10 µM Ferr-1 (Ferrostatin-1), 20 µM Nec-1 (Necrostatin-1), 10 µM Z-VAD-FMK, and 1 mM NAC.

    Z-VAD-FMK purchased from MedChemExpress. Usage Cited in: Adv Funct Mater. 2023 May 14.

    The viability of MC38 cells treated with (A) MTO, (B) SAS, (C) M+S, and (D) PD@MS for 48 h in the presence or absence of 10 µM Ferr-1, 20 µM Nec-1, 10 µM Z-VADFMK, and 1 mM NAC.

    Z-VAD-FMK purchased from MedChemExpress. Usage Cited in: Nat Microbiol. 2022 Jul;7(7):1041-1053.  [Abstract]

    HFFs stably expressing UL37x1 or empty vector are infected with HCMV in the presence of z-VAD-FMK. At 0, 6 and 12 h.

    Z-VAD-FMK purchased from MedChemExpress. Usage Cited in: Redox Biol. 2022 Oct;56:102435.  [Abstract]

    Primary HSCs and LX-2 cells are treated with EA (LX-2 cells: 40 μM; primary HSCs: 45 μM), Ferrostatin-1 (1 μM) and Z-VAD-FMK (10 μM), and cells are stained with PI (red fluorescence) to examine the dead cells.

    Z-VAD-FMK purchased from MedChemExpress. Usage Cited in: Redox Biol. 2022 Aug;54:102355.

    In CAL-27 cells, Z-VAD-FMK (50 μM; 4 hours) treatment counteracted the NRC-03-induced cytotoxicity and apoptosis.

    Z-VAD-FMK purchased from MedChemExpress. Usage Cited in: J Autoimmun. 2022 Dec:133:102904.  [Abstract]

    C57BL/6 are treated with Concanavalin A (12 μg/g) alone or zVAD (20 μg/g) alone or zVAD (20 μg/g) + Concanavalin A (12 μg/g) at indicated times. The number of apoptotic cells in the zVAD + Concanavalin A treated group is markedly reduced compared with that observed in the ConA-treated group.

    Z-VAD-FMK purchased from MedChemExpress. Usage Cited in: J Autoimmun. 2022 Dec:133:102904.  [Abstract]

    After being treated with zVAD (0, 20, 40, 80 μM) for 30 min, the BMDMs are followed by the administration of LPS (100 ng/ml) for 24 h.

    Z-VAD-FMK purchased from MedChemExpress. Usage Cited in: J Autoimmun. 2022 Dec:133:102904.  [Abstract]

    The BMDMs are cultured with different concentrations of zVAD (0, 20, 40, 80, 100 μM) for 24 h.

    Z-VAD-FMK purchased from MedChemExpress. Usage Cited in: Phytother Res. 2023 Feb;37(2):689-701.  [Abstract]

    z-VAD-fmk (5 μM; 4 h) weakens CDBEE-induced apoptosis in MGC-803 and HGC-27 cells.

    Z-VAD-FMK purchased from MedChemExpress. Usage Cited in: Bioact Mater. 2021 Nov 19;13:23-36.  [Abstract]

    H1299 and H460 cells are treated with curcumenol with or without Z-VAD-FMK (10 μM) for 24 h, the cell viability is detected.

    Z-VAD-FMK purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2021 Feb 8;8(8):2002874.  [Abstract]

    In vitro growth of KYSE30 cells expressing EV or OTUD1 and treated with or without Z‐VAD-FMK (50 μM).

    Z-VAD-FMK purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2021 Feb 8;8(8):2002874.  [Abstract]

    Representative image and statistical analyses of JC‐1 staining of KYSE30 cells expressing EV or OTUD1 and treated with DDP or Z‐VAD-FMK (50 μM). Z‐VAD-FMK treatment could not completely inhibit the proapoptotic function of OTUD1.

    Z-VAD-FMK purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2021 Feb 8;8(8):2002874.  [Abstract]

    IB further confirmed the activation of the caspase‐dependent apoptotic pathway in OTUD1‐overexpressing cells with AIF ablation, which is diminished by VAD-FMK (50 μM).

    Z-VAD-FMK purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2021 May;11(5):1246-1260.

    Apoptosis of ECa109 and EC9706 cells treated with SFN (40 μM) and Z-VAD-FMK (20 μM) alone or combination for 48 h is analyzed by flow cytometry.

    Z-VAD-FMK purchased from MedChemExpress. Usage Cited in: Theranostics. 2020 Jun 19;10(17):7710-7729.  [Abstract]

    When the cells were co-treated with Z-VAD-FMK (50 μM; 24 hours), the F-AgÅPs-induced inhibition of survival of 143B and SJSA-1 is significantly attenuated, as revealed by live/dead cell staining.

    Z-VAD-FMK purchased from MedChemExpress. Usage Cited in: Acta Biomater. 2020 Jun;109:229-243.  [Abstract]

    The decreased cleaved caspase-3 and Bax proteins showed that Z-VAD successfully inhibited Chemo-PDT induced apoptosis.

    Caspase アイソフォーム固有の製品をすべて表示:

    すべてのアイソフォームを表示
    Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

    RIP kinase アイソフォーム固有の製品をすべて表示:

    すべてのアイソフォームを表示
    RIPK1 RIPK2 RIPK3

    Glutathione Peroxidase アイソフォーム固有の製品をすべて表示:

    すべてのアイソフォームを表示
    GPX1 GPX4

    • 生物活性

    • 純度とドキュメンテーション

    • 参考文献

    • カスタマーレビュー

    製品説明

    Z-VAD-FMK is a pan-caspase inhibitor and also an ICE-like protease inhibitor, which inhibits apoptosis by preventing the processing of CPP32 to its active form. Z-VAD-FMK sensitivity varies primarily due to differential expression of receptor-interacting protein 1 (RIP1). Z-VAD-FMK limits the cryopreservation-induced apoptosis by reducing caspase-3 activity of in vitro produced bovine embryos. Z-VAD-FMK is immunosuppressive in vitro and inhibits T cell proliferation without blocking the processing of caspase-8 and caspase-3. Z-VAD-FMK leads to a decrease in intracellular glutathione (GSH) with a concomitant increase in reactive oxygen species (ROS) levels in activated T cells. Z-VAD-FMK is due to oxidative stress via the depletion of GSH. Z-VAD-FMK can be used for the study of acute pancreatitis[1][2][3][4][5][6][7].

    IC50 & Target[1]

    Caspase

     

    体外実験

    Z-VAD-FMK (100 μM, 8 h) can induce both autophagy and necrosis in J774A.1 macrophages, indicating that it can trigger non-apoptotic cell death pathways[2].
    Z-VAD-FMK (20 μM, 48 h) significantly improves the cryotolerance of Bovine in vitro produced blastocysts by inhibiting apoptosis, and improves the survival and development of embryos after thawing[3].
    Z-VAD-FMK (20 μM, 48 h) directly inhibits caspase-3 activation, demonstrating that it improves the cryotolerance of bovine blastocysts by blocking the apoptosis pathway[3].
    Z-VAD-FMK (0-100 μM, 72 h) dose-dependently inhibits T cell proliferation mediated through the co-stimulation with anti-CD3 and anti-CD28[4].
    Z-VAD-FMK (50-100 μM, 16 h) significantly inhibits FasL-induced T cell apoptosis and caspase-8/caspase-3 treatment[4].
    Z-VAD-FMK (25-100 μM, 6-24 h) can deplete and activate GSH in anti-CD3 antibody-pretreated peripheral blood mononuclear cells (PBMCs) following prolonged incubation[5].
    Z-VAD-FMK (25-100 μM, 6-24 h) significantly increases ROS levels in primary T cells[5].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Z-VAD-FMK 関連抗体

    Western Blot Analysis[4]

    Cell Line: FasL-induced T cells
    Concentration: 50 μM, 100 μM
    Incubation Time: 16 h
    Result: Effectively inhibited caspase activity in the apoptosis model, but had no effect on T cell activation.
    体内実験

    Z-VAD-FMK (3 mg/kg, i.p., once every other day, for 3 months) can reduce inflammation and mucus secretion in mice induced by cigarette smoke[6].
    Z-VAD-FMK (50 μmol/L (0.3 mL), i.p., 30 mins before modeling) significantly reduces severe acute pancreatitis (SAP)-induced lung tissue pathological damage in a SAP model in rats[7].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Thirty-two 6-7-week-old male C57BL/6J mice were exposed to cigarette smoke (CS)[6].
    Dosage: 3 mg/kg
    Administration: I.P., once every other day, for 3 months
    Result: Significantly reduced airway inflammation and emphysema lesions caused by CS exposure.
    Lowered serum IL-1β, IL-8, and IL-1β levels in BALF.
    Had no significant inhibitory effect on mucus secretion (Muc5ac).
    Animal Model: Seventy-two male Sprague-Dawley rats (weighing 250-300 g) were anesthetized by intraperitoneal injection of ketamine (100 mg/kg), followed by laparotomy and retrograde injection of 5% sodium taurocholate (1.0 mL/kg) into the pancreatic duct via the duodenal papilla[7].
    Dosage: 50 μmol/L (0.3 mL)
    Administration: I.p., 30 mins before modeling
    Result: Significantly alleviated SAP-induced pathological damage to lung tissue (edema, inflammatory infiltration, and hemorrhage).
    Inhibiting cleaved caspase-3 expression blocked lung cell apoptosis.
    Reduced myeloperoxidase (MPO) activity and inflammatory cytokine (IL-1β, TNF-α) levels, inhibiting neutrophil infiltration and inflammatory responses.
    分子量

    453.46

    分子式

    C21H28FN3O7
    CAS 番号
    Appearance

    Solid

    Color

    White to light yellow

    SMILES

    O=C(N[C@H](C(N[C@@H](C)C(N[C@@H](CC(O)=O)C(CF)=O)=O)=O)C(C)C)OCC1=CC=CC=C1
    輸送条件

    Room temperature in continental US; may vary elsewhere.
    保管条件

    4°C, sealed storage, away from moisture and light

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
    溶剤 & 溶解度
    体外: 

    DMSO : 100 mg/mL (220.53 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.2053 mL 11.0263 mL 22.0527 mL
    5 mM 0.4411 mL 2.2053 mL 4.4105 mL
    10 mM 0.2205 mL 1.1026 mL 2.2053 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます：C1V1 = C2V2

    濃度 （開始）

    C1

    ×
    体積 （開始）

    V1

    =
    濃度 （終了）

    C2

    ×
    体積 （終了）

    V2

    体内:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (4.59 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: 2.08 mg/mL (4.59 mM); Suspended solution; Need ultrasonic

      This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    純度とドキュメンテーション

    純度: 99.76%

    COA (246 KB) HNMR (263 KB) LCMS (119 KB)

    取扱説明書 (2659 KB)
    参考文献

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.2053 mL 11.0263 mL 22.0527 mL 55.1317 mL
    5 mM 0.4411 mL 2.2053 mL 4.4105 mL 11.0263 mL
    10 mM 0.2205 mL 1.1026 mL 2.2053 mL 5.5132 mL
    15 mM 0.1470 mL 0.7351 mL 1.4702 mL 3.6754 mL
    20 mM 0.1103 mL 0.5513 mL 1.1026 mL 2.7566 mL
    25 mM 0.0882 mL 0.4411 mL 0.8821 mL 2.2053 mL
    30 mM 0.0735 mL 0.3675 mL 0.7351 mL 1.8377 mL
    40 mM 0.0551 mL 0.2757 mL 0.5513 mL 1.3783 mL
    50 mM 0.0441 mL 0.2205 mL 0.4411 mL 1.1026 mL
    60 mM 0.0368 mL 0.1838 mL 0.3675 mL 0.9189 mL
    80 mM 0.0276 mL 0.1378 mL 0.2757 mL 0.6891 mL
    100 mM 0.0221 mL 0.1103 mL 0.2205 mL 0.5513 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Z-VAD-FMK Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質量   濃度   体積   分子量 *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます：C1V1 = C2V2

    濃度 （開始） × 体積 （開始） = 濃度 （終了） × 体積 （終了）
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Z-VAD-FMK161401-82-7Z-VAD(OH)-FMKCaspaseApoptosisRIP kinaseGlutathione PeroxidaseReactive Oxygen Species (ROS)Receptor-interacting protein kinasesRIPKAtherosclerosisAutophagyNecrosisSmoothmuscle CellReceptor-interacting Protein 1CytokinesChemokinesCaspasesCell death pathwaysInflammationInhibitorinhibitorinhibit

    最近チェックした製品:

    オンラインお問い合わせ

    Your information is safe with us. * Required Fields.

    製品名

    		  

    カスタマ需要量 *

    お名前 *

    		 

    タイトル

    メールアドレス *

    		 

    電話番号 *

    デパートメント

    		 

    組纖名 *

    市区町村

    都道府県

    国或いは地域 *

    		      

    必ず会社名を記載ください。個人への返信は行いません。

    備考

    バルクお問い合わせ

    Inquiry Information

    製品名:
    Z-VAD-FMK
    製品番号:
    HY-16658B
    数量:
    MCE 日本正規代理店:

    カスタマーレビュー

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    製品名

    		  

    Lot #

    お名前 *

    		 

    メールアドレス *

    電話番号 *

    		 

    部門 *

    組纖名 *

    		 

    国或いは地域 *

    備考

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.